Kurs & Likviditet
|2022-04-29||Ordinarie utdelning VIRO 0.00 DKK|
|2021-04-28||Ordinarie utdelning VIRO 0.00 DKK|
|2020-06-19||Ordinarie utdelning VIRO 0.00 DKK|
|2019-04-26||Ordinarie utdelning VIRO 0.00 DKK|
|Lista||First North Denmark|
4.3.2022 12:30:34 CET | ViroGates | Company Announcement
COMPANY ANNOUNCEMENT - No. 04-2022 – inside information 4 March 2022
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces that the distribution partner in Germany bestbion dx GmbH has started successful selling suPARnostic® for clinical use, to guide anakinra treatment in adult COVID-19 patients, in several hospitals in the German market.
ViroGates are supplying products to bestbion dx on a centralized basis and cannot inform of details of the individual accounts.
Jakob Knudsen, CEO of ViroGates, says: ”We are delighted to see the first clinical sales materializing in the German market following the approval of suPARnostic® guided anakinra treatment in December. We are happy to see that our relatively newly established collaboration with bestbion dx is working so well and that the market is now appreciating this new opportunity for the identification and treatment of severely affected COVID-19 patients. We expect that this will be a first step in the introduction of our products in Germany and that the market will also start using suPARnostic® for general triage in the emergency departments when the pandemic is more tightly controlled.”
Bernd Stammel, Founder of bestbion dx says: “In our continuous search for innovative biomarkers to improve clinical care we’ve recently added this promising biomarker to our product portfolio. We have been working with the promotion of suPARnostic® in Germany for the last year now and are very happy about the recent clinical data that will facilitate clinical routine use at hospitals in Germany. We are excited about the prospects of helping hospitals to care for patients with serious illness due to COVID-19 disease.”
The announcement can be found at https://www.virogates.com/investor/announcements.
For further information, please contact:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: email@example.com
Västra Hamnen Corporate Finance
Tel. (+46) 40 200 250, email: firstname.lastname@example.org
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, France and Benelux, while distributors serve other markets.
ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, visit www.virogates.com.
About suPAR and suPARnostic®
suPAR is a biomarker detected by ViroGates' suPARnostic® products. It is a protein found in the plasma. suPAR is considered a general risk status biomarker indicating inflammation and can indicate disease presence, severity, and progression across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 800 clinical trials and studies shows that the higher the level of suPAR, the worse the prognosis for the patient.
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalisation or discharge of acute care patients. The increasing global demands on health systems and tightening healthcare budgets necessitate efficiency improvements and innovative hospital solutions. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length of stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics' cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments and the Abbott Labs Architect™ and Alinity™ instruments. ViroGates works with partners to develop solutions for other platforms.
About bestbion dx GmbH
Leading international manufacturers count on bestbion dx GmbH for marketing and distribution of their products in Germany and Austria.
bestbion dx inspires with an almost 100% delivery capability and more than just personal customer service.
In order to meet the requirements and problems of their customers, bestbion dx combines agile start-up culture with over 30 years of experience in laboratory diagnostics. Both, in active sales as well as in establishing contacts with international manufacturers. This combination allows the company to act particularly flexible on the market and make a sustainable contribution to innovative laboratory diagnostics.
The bestbion dx team breathes its philosophy "saving humans and preserving lives"! Fast, uncomplicated and especially personal support for their customers is therefore the companies declared objective.
Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
- Jakob Knudsen, CEO, +45 2226 1355, email@example.com